|Title:||Effects of a Mediterranean eating plan on the need for glucose-lowering medications in participants with type 2 diabetes: A subgroup analysis of the PREDIMED trial||Authors:||Javier Basterra-Gortari, F.
Martínez-González, Miguel A.
Sorlí, José V.
Serra Majem, Luis
González, José I.
|UNESCO Clasification:||32 Ciencias médicas||Keywords:||Cardiovascular Risk-Factors
Mellitus, et al
|Issue Date:||2019||Journal:||Diabetes Care||Abstract:||Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license. OBJECTIVE To examine the effects of two Mediterranean eating plans (Med-EatPlans) versus a low-fat eating plan on the need for glucose-lowering medications. RESEARCH DESIGN AND METHODS From the Prevención con Dieta Mediterránea (PREDIMED) trial, we selected 3,230 participants with type 2 diabetes at baseline. These participants were randomly assigned to one of three eating plans: Med-EatPlan supplemented with extra-virgin olive oil (EVOO), Med-EatPlan supplemented with mixed nuts, or a low-fat eating plan (control). In a subgroup (15%), the allocation was done in small clusters instead of using individual randomization, and the clustering effect was taken into account in the statistical analysis. In multivariable time-to-event survival models, we assessed two outcomes: 1) introduction of the first glucose-lowering medication (oral or injectable) among participants on lifestyle management at enrollment and 2) insulin initiation. RESULTS After a median follow-up of 3.2 years, in multivariable analyses adjusting for baseline characteristics and propensity scores, the hazard ratios (HRs) of starting a first glucose-lowering medication were 0.78 (95% CI 0.62-0.98) for Med-EatPlan + EVOO and 0.89 (0.71-1.12) for Med-EatPlan + nuts, compared with the control eating plan. After a median follow-up of 5.1 years, the adjusted HRs of starting insulin treatment were 0.87 (0.68-1.11) for Med-EatPlan + EVOO and 0.89 (0.69-1.14) for Med-EatPlan + nuts compared with the control eating plan. CONCLUSIONS Among participants with type 2 diabetes, a Med-EatPlan + EVOO may delay the introduction of new-onset glucose-lowering medications. The Med-EatPlan did not result in a significantly lower need for insulin.||URI:||http://hdl.handle.net/10553/69989||ISSN:||0149-5992||DOI:||10.2337/dc18-2475||Source:||Diabetes Care [ISSN 0149-5992], v. 42 (8), p. 1390-1397|
|Appears in Collections:||Artículos|
checked on Jun 4, 2023
WEB OF SCIENCETM
checked on Oct 2, 2022
checked on Jun 3, 2023
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.